XML 39 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Account Detail (Tables)
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Cash and Cash Equivalents and Marketable Securities The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”:
Historical or Amortized CostFair ValueCash and Cash
Equivalents		Marketable Securities
December 31, 2021
Money market funds$66,322 $66,322 $66,322 $— 
Equity securities(1)
3,512 5,718 — 5,718 
Mutual funds 5,218 6,390 — 6,390 
Bank deposits22,217 22,217 22,217 — 
Total cash and cash equivalents and marketable securities$97,269 $100,647 $88,539 $12,108 
December 31, 2020
Money market funds$40,560 $40,560 $40,560 $— 
Equity securities3,764 24,946 — 24,946 
Government-related debt securities92,881 92,928 — 92,928 
Corporate debt securities8,846 8,848 — 8,848 
Mutual funds4,497 5,573 — 5,573 
Bank CDs1,715 1,721 — 1,721 
Bank deposits5,449 5,449 5,449 — 
Total cash and cash equivalents and marketable securities$157,712 $180,025 $46,009 $134,016 
 (1)Our aggregate equity holdings consist of 5.1 million common shares of CASI Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, with a fair market value of $4.0 million as of December 31, 2021. We completed the sale of 3.4 million shares of common stock and recognized a $5.7 million gain within “other expense, net” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2021. Additionally, we hold 0.8 million common shares of Unicycive Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, with a fair market value of $1.7 million as of December 31, 2021.
Schedule of Other Receivables “Other receivables” consists of the following:
December 31,
20212020
Other miscellaneous receivables$685 $901 
Employee receivable341 — 
Income tax receivable - current portion— 1,297 
Interest receivable from marketable securities2 196 
Other receivables$1,028 $2,394 
Schedule of Prepaid Expenses and Other Assets
“Prepaid expenses and other current assets” consists of the following:
December 31,
20212020
Prepaid expenses and deferred costs$1,550 $1,996 
Prepaid insurance727 2,165 
Prepaid expenses and other current assets$2,277 $4,161 
Schedule of Property and Equipment, net
“Property and equipment, net” consists of the following:
December 31,
20212020
Manufacturing equipment$— $3,245 
Computer hardware and software1,803 1,680 
Laboratory equipment5 5 
Office furniture317 248 
Leasehold improvements1,278 1,267 
Property and equipment, at cost3,403 6,445 
(Less): Accumulated depreciation(2,948)(2,868)
Property and equipment, net $455 $3,577 

Depreciation expense was immaterial for the years ended December 31, 2021 and 2020, respectively.
Schedule of Accounts Payable and Other Accrued Liabilities “Accounts payable and other accrued liabilities” consists of the following:
 December 31,
 20212020
Trade accounts payable and other$33,408 $34,385 
Lease liability - current portion1,282 1,544 
Commercial Product Portfolio accruals (Note 9)6,568 7,842 
Accounts payable and other accrued liabilities$41,258 $43,771 
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Consolidated Balance Sheets for our categories of gross-to-net (“GTN”) estimates related to the Commercial Product Portfolio accruals were as follows:
Commercial/Medicaid Rebates and Government ChargebacksDistribution,
Data, Inventory, and
GPO Administrative
Fees		Product Return AllowancesTotal
Balance as of December 31, 2019$14,671 $1,138 $4,714 $20,523 
(Less): Payments and credits against GTN accruals(12,070)(196)(415)(12,681)
Balance as of December 31, 20202,601 942 4,299 7,842 
(Less): Payments and credits against GTN accruals(1,159)— (115)(1,274)
Balance as of December 31, 2021$1,442 $942 $4,184 $6,568